z-logo
Premium
Perianal mucinous adenocarcinoma
Author(s) -
Anthony Thomas,
Simmang Clifford,
Lee Edward L.,
Turnage Richard H.
Publication year - 1997
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199703)64:3<218::aid-jso8>3.0.co;2-d
Subject(s) - medicine , abdominoperineal resection , adenocarcinoma , surgery , rare disease , radiation therapy , presentation (obstetrics) , fistula , disease , cancer , colorectal cancer
Background Perianal mucinous adenocarcinoma is a rare variant of anal canal epithelioid tumors. Our objective in this report is to examine the clinical features, pathology, treatment, and outcome for patients with perianal mucinous adenocarcinoma. Methods A retrospective review identified four patients with histologically proven perianal mucinous adenocarcinoma. The medical records of these patients were reviewed for presentation, therapy, and outcome. Results Pain and bleeding were present in all cases. In three of four patients, chronic perirectal disease was present, including two abscesses and one fistula. All patients had extensive local disease at presentation. One patient presented with bilateral inguinal nodal metastases. Two patients received neoadjuvant chemotherapy and radiation, with a third patient receiving radiation alone. Two of these three patients underwent abdominoperineal resection. Three patients subsequently died (all of progression and/or recurrence) 2–48 months after diagnosis. The fourth patient (who was treated with chemotherapy and radiation followed by abdominoperineal resection) is alive and disease free at 12 months. Conclusions Perianal mucinous adenocarcinoma is a rare disease with a poor prognosis, mostly due to its advanced nature at the time of diagnosis. Chemoradiation followed by surgery may improve outcome in selected individuals. J. Surg. Oncol. 64:218–221 © 1997 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here